DPP4 and COVID-19: New expectations rose when recent reports revealed significant reductions in admissions to ICU and mortality in DPP4 inhibitor users of up to 24% [59,60,61,62,63], with several authors suggesting that targeting DPP4 could be a pharmacologically important strategy for treating patients suffering from severe respiratory diseases related to coronaviruses and COVID-19 [64,65].